Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

UroGen Pharma (URGN) EBT Margin (2017 - 2025)

UroGen Pharma (URGN) has disclosed EBT Margin for 9 consecutive years, with 70.4% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBT Margin rose 7152.0% year-over-year to 70.4%, compared with a TTM value of 139.74% through Dec 2025, down 252.0%, and an annual FY2025 reading of 139.74%, down 252.0% over the prior year.
  • EBT Margin was 70.4% for Q4 2025 at UroGen Pharma, up from 125.18% in the prior quarter.
  • Across five years, EBT Margin topped out at 70.4% in Q4 2025 and bottomed at 346.49% in Q1 2021.
  • Average EBT Margin over 5 years is 166.02%, with a median of 158.31% recorded in 2022.
  • The sharpest move saw EBT Margin soared 822833bps in 2021, then tumbled -4933bps in 2025.
  • Year by year, EBT Margin stood at 168.88% in 2021, then rose by 8bps to 155.76% in 2022, then surged by 40bps to 94.19% in 2023, then tumbled by -51bps to 141.92% in 2024, then soared by 50bps to 70.4% in 2025.
  • Business Quant data shows EBT Margin for URGN at 70.4% in Q4 2025, 125.18% in Q3 2025, and 202.04% in Q2 2025.